|
Post by joeypotsandpans on Nov 7, 2017 19:58:50 GMT -5
Mike mentioned they're watching how two lawsuits between a couple of the large Pharma plays out, it plays into pricing etc. and anti-competitive practices if I recall correctly, was working while I overheard it. Will look at the transcripts to get a better idea of the context it was mentioned in.
|
|
|
Post by factspls88 on Nov 7, 2017 20:01:50 GMT -5
I was disturbed by the comment by Jason about Dendreon. That, combined with the recent Cramer and Feuerstein bashings smacks of a conspiracy to destroy the stock and company. I thought we had gotten past that but I guess not. That said, I am happy about the TV campaign and increases in cartridges. As for PBMs, I would like to have heard more specifics regarding who has signed on for 2018 that were not on board in 2017 or who have improved Afrezza's accessibility with respect to classification (PA, Preferred, etc). Not sure if you caught it or maybe I was hearing things but when Mike began to respond he let out a little bit of a laugh....that individual that asked that was so far out of his league, like Mike a PharmD (who was an executive at AMGN) wouldn't know that process and prohibitive cost of the cancer treatment associated with DNDN. In there case, as Mike stated, it is totally an apples to oranges situation and Mike tactfully educated (and it is questionable that the individual asking the question was intelligent to know the difference to begin with) in a concise response the night and day differences. Facts, the recent reawakening of the dark side only enforces their desperation, otherwise they wouldn't sound a peep but they thought the game was over and got complacent and woke up about a month ago when the MM's were scrambling to keep up when the volcano gave it's warning eruption...notice the preface of warning. I'm actually encouraged with the recent spate of puppets waking up....I've been having a bit of fun with SO and his lemmings, very entertaining to say the least I was just relistening to the call while you were posting and heard the same thing, i.e. the laugh. I think the ad plan is an excellent one and exactly what they should be doing given their resources and I'm looking forward to the results. I'm glad you're having fun with the dark side......I just wish they'd go away
|
|
|
Post by mnkdfann on Nov 7, 2017 20:01:56 GMT -5
I was disturbed by the comment by Jason about Dendreon. That, combined with the recent Cramer and Feuerstein bashings smacks of a conspiracy to destroy the stock and company. I thought we had gotten past that but I guess not. That said, I am happy about the TV campaign and increases in cartridges. As for PBMs, I would like to have heard more specifics regarding who has signed on for 2018 that were not on board in 2017 or who have improved Afrezza's accessibility with respect to classification (PA, Preferred, etc). Not sure if you caught it or maybe I was hearing things but when Mike began to respond he let out a little bit of a laugh....that individual that asked that was so far out of his league It's funny, insomuch as that individual (Jason from Maxim) was a hero on this board not so long ago. mnkd.proboards.com/thread/8371/maxim-group-starts-mnkd-buy
|
|
|
Post by mango on Nov 7, 2017 20:16:19 GMT -5
Mike said to Jason that 98% of patients weren't aware that Afrezza even existed.
A few things come to mind:
1) The non-profit charity organization that creates the Standards of Care seem to be tied up in conflicting financial interests that creates biasness and hinders the awareness of Afrezza to people with diabetes.
2) The Endo Consensus is tied up in conflicting financial interests which hinders the awareness of Afrezza to people with diabetes.
3) The AACE and the ACE are tied up in conflicting financial interests which hinders the awareness of Afrezza to people with diabetes.
|
|
|
Post by sportsrancho on Nov 7, 2017 20:36:47 GMT -5
Not sure if you caught it or maybe I was hearing things but when Mike began to respond he let out a little bit of a laugh....that individual that asked that was so far out of his league, like Mike a PharmD (who was an executive at AMGN) wouldn't know that process and prohibitive cost of the cancer treatment associated with DNDN. In there case, as Mike stated, it is totally an apples to oranges situation and Mike tactfully educated (and it is questionable that the individual asking the question was intelligent to know the difference to begin with) in a concise response the night and day differences. Facts, the recent reawakening of the dark side only enforces their desperation, otherwise they wouldn't sound a peep but they thought the game was over and got complacent and woke up about a month ago when the MM's were scrambling to keep up when the volcano gave it's warning eruption...notice the preface of warning. I'm actually encouraged with the recent spate of puppets waking up....I've been having a bit of fun with SO and his lemmings, very entertaining to say the least I was just relistening to the call while you were posting and heard the same thing, i.e. the laugh. I think the ad plan is an excellent one and exactly what they should be doing given their resources and I'm looking forward to the results. I'm glad you're having fun with the dark side......I just wish they'd go away Yeah Jason needs to go hide under a rock somewhere. What a about face! Heard the laugh loud and clear:-) Of all things to bring up! Never a dull moment. Joey, yes I loved the confidence versus ego explanation:-) Agree
|
|
|
Post by dreamboatcruise on Nov 7, 2017 20:38:54 GMT -5
I was disturbed by the comment by Jason about Dendreon. That, combined with the recent Cramer and Feuerstein bashings smacks of a conspiracy to destroy the stock and company. I thought we had gotten past that but I guess not. That said, I am happy about the TV campaign and increases in cartridges. As for PBMs, I would like to have heard more specifics regarding who has signed on for 2018 that were not on board in 2017 or who have improved Afrezza's accessibility with respect to classification (PA, Preferred, etc). Hopefully at least one "big" insurer has already been finalized as was previously eluded to, but in general it sounds like now they are setting expectations that some payers will start evaluating the the "category" (prandial insulin) likely in Q1. I did find the statements about this on the call too encouraging regarding the time line over which it will play out and translate to script growth.
|
|
|
Post by dreamboatcruise on Nov 7, 2017 20:44:04 GMT -5
as far as I could tell, "talks", no sign. You're probably right. What happened to the big payor that was supposed to be signing on? I thought that Mike might have been keeping quiet for competitive reasons. It easily could be that payers simply have NDA in agreements that say no release of info until the formulary is published.
|
|
|
Post by brentie on Nov 7, 2017 21:14:30 GMT -5
|
|
|
Post by dreamboatcruise on Nov 7, 2017 22:06:29 GMT -5
brentie... thanks for the links. Though side note, I find your new image a bit disturbing Perhaps it doesn't seem the same to others, but that doesn't look like a cat that is enjoying himself. To me he looks stuck and panicked. It makes me sad whenever I see it.
|
|
|
Post by nylefty on Nov 7, 2017 22:21:56 GMT -5
brentie ... thanks for the links. Though side note, I find your new image a bit disturbing Perhaps it doesn't seem the same to others, but that doesn't look like a cat that is enjoying himself. To me he looks stuck and panicked. It makes me sad whenever I see it. More than a little disturbing.
|
|
|
Post by factspls88 on Nov 7, 2017 22:23:02 GMT -5
brentie ... thanks for the links. Though side note, I find your new image a bit disturbing Perhaps it doesn't seem the same to others, but that doesn't look like a cat that is enjoying himself. To me he looks stuck and panicked. It makes me sad whenever I see it. I think that cat got a good look at your image and ran for the nearest available cover
|
|
|
Post by mnholdem on Nov 7, 2017 23:10:56 GMT -5
brentie ... thanks for the links. Though side note, I find your new image a bit disturbing Perhaps it doesn't seem the same to others, but that doesn't look like a cat that is enjoying himself. To me he looks stuck and panicked. It makes me sad whenever I see it. More than a little disturbing. I think that's spiro's cat looking for the last Mallomar, isn't it?
|
|
|
Post by joeypotsandpans on Nov 7, 2017 23:39:14 GMT -5
Mike mentioned they're watching how two lawsuits between a couple of the large Pharma plays out, it plays into pricing etc. and anti-competitive practices if I recall correctly, was working while I overheard it. Will look at the transcripts to get a better idea of the context it was mentioned in. It was Pat not Mike, here is the excerpt which I think is sooooo important regarding the situation with the payors, etc.: Patrick McCauley I mean I think you have seen two lawsuits, one Pfizer versus J&J and one Shire versus Allergen looking at the some of the market behaviors around access to care on different product profiles. This is something we're watching closely and studying. We've had many good discussions with the payers and we have a lot of good support out there with thought leaders as well as patient advocates. And so we know we have a slightly higher dropout rate because of the actions between the competition as well as the payer. But we also have a lot of success given our limited contracted lives. Remember we only contract for roughly 20% of all the prescriptions. And so as we go out there we get 70% to 80% coverage when we do the prior authorization works. So the doctors play for the patient, those get approved many times even though we don't contract for that business. So it makes sense for payer now with this new data to really revaluate some of those previous decisions honestly that were made three years ago under the regime of Sanofi and so very few categories reviews have happened in the last two years as there hasn't been much innovation on mealtime influence. With this label change I can tell you a few of payers are reviewing the category in Q1 and we do expect to continue that good progress there. But it's always been about these payers but we feel good about to the direction and the discussions that were going on.
|
|
|
Post by brentie on Nov 7, 2017 23:46:08 GMT -5
More than a little disturbing. I think that's spiro's cat looking for the last Mallomar, isn't it? OK, how's this?
|
|
|
Post by dreamboatcruise on Nov 8, 2017 2:18:26 GMT -5
Mike mentioned they're watching how two lawsuits between a couple of the large Pharma plays out, it plays into pricing etc. and anti-competitive practices if I recall correctly, was working while I overheard it. Will look at the transcripts to get a better idea of the context it was mentioned in. It was Pat not Mike, here is the excerpt which I think is sooooo important regarding the situation with the payors, etc.: Patrick McCauley I mean I think you have seen two lawsuits, one Pfizer versus J&J and one Shire versus Allergen looking at the some of the market behaviors around access to care on different product profiles. This is something we're watching closely and studying. We've had many good discussions with the payers and we have a lot of good support out there with thought leaders as well as patient advocates. And so we know we have a slightly higher dropout rate because of the actions between the competition as well as the payer. But we also have a lot of success given our limited contracted lives. Remember we only contract for roughly 20% of all the prescriptions. And so as we go out there we get 70% to 80% coverage when we do the prior authorization works. So the doctors play for the patient, those get approved many times even though we don't contract for that business. So it makes sense for payer now with this new data to really revaluate some of those previous decisions honestly that were made three years ago under the regime of Sanofi and so very few categories reviews have happened in the last two years as there hasn't been much innovation on mealtime influence. With this label change I can tell you a few of payers are reviewing the category in Q1 and we do expect to continue that good progress there. But it's always been about these payers but we feel good about to the direction and the discussions that were going on. Actually I don't remember anything ever being said about this. Can someone refresh my memory about what this means and when we were told about it? I'm getting old so I'm sure it's just slipping my mind.
|
|